Summary
Keryx Biopharmaceuticals Inc (Keryx) is a biopharmaceutical company which develops and commercializes innovative therapies for the treatment of renal disease. The company’s lead product Auryxia (ferric citrate) is an FDA approved oral, absorbable iron-based compound. It has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes. Auryxia is used in the treatment of chronic kidney disease, renal diseases and iron deficiency anemia. This product is also marketed in Japan under the brand name Riona through its Japanese partner Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. The company operates through its subsidiaries and also has its operational presence with its offices located in New York, and Boston in the US; the UK and Israel. Keryx is headquartered in New York, the US.
Keryx Biopharmaceuticals Inc (KERX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Equity Offering 10
Keryx Biopharma Plans to Raise up to USD75 Million in Public Offering of Shares 10
Keryx Biopharma Prices Public Offering of Shares for USD110 Million 11
Keryx Biopharma Completes Public Offering Of Shares For US$115 Million 12
Keryx Biopharma Completes Public Offering Of Shares For US$80 Million 14
Keryx BioPharma Completes Underwritten Public Offering Of US$33 Million 15
Debt Offering 17
Keryx Biopharma to Raise USD125 Million in Private Placement of Notes Due 2020 17
Acquisition 18
Baupost Acquires 10.7% Stake In Keryx Biopharma 18
Keryx Biopharmaceuticals Inc - Key Competitors 19
Key Employees 20
Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22List of Tables
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Keryx Biopharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Keryx Biopharma Plans to Raise up to USD75 Million in Public Offering of Shares 10
Keryx Biopharma Prices Public Offering of Shares for USD110 Million 11
Keryx Biopharma Completes Public Offering Of Shares For US$115 Million 12
Keryx Biopharma Completes Public Offering Of Shares For US$80 Million 14
Keryx BioPharma Completes Underwritten Public Offering Of US$33 Million 15
Keryx Biopharma to Raise USD125 Million in Private Placement of Notes Due 2020 17
Baupost Acquires 10.7% Stake In Keryx Biopharma 18
Keryx Biopharmaceuticals Inc, Key Competitors 19
Keryx Biopharmaceuticals Inc, Key Employees 20
Keryx Biopharmaceuticals Inc, Subsidiaries 21List of Figures
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
